EML4-ALK AND ITS INHIBITORS: A NEW PARADIGM IN CANCER TREATMENT

被引：0
|
作者：
Mano, H. [1 ,2 ]
机构：
[1] Jichi Med Univ, Div Funct Genom, Shimotsuke, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Med Genom, Tokyo 1138654, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [41] Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
    Aydemirli, Mehtap Derya
    van Eendenburg, Jaap D. H.
    van Wezel, Tom
    Oosting, Jan
    Corver, Willem E.
    Kapiteijn, Ellen
    Morreau, Hans
    ENDOCRINE-RELATED CANCER, 2021, 28 (06) : 377 - 389
  • [42] A RATIONAL DIAGNOSTIC ALGORITHM FOR THE IDENTIFICATION OF EML4-ALK TRANSLOCATION IN LUNG CANCER
    Takamochi, Kazuva
    Oh, Shiaki
    Suzuki, Kenji
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S462 - S462
  • [43] EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer
    Gower, Arjan
    Hsu, Wei-Hsun
    Hsu, Shuo-Tse
    Wang, Yisong
    Giaccone, Giuseppe
    MOLECULAR ONCOLOGY, 2016, 10 (04) : 601 - 609
  • [44] Membrane Phospholipids, EML4-ALK, and Hsp90 as Novel Targets in Lung Cancer Treatment
    Laszlo, Andrei
    Thotala, Dinesh
    Hallahan, Dennis E.
    CANCER JOURNAL, 2013, 19 (03): : 238 - 246
  • [45] EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer
    Hui, Beina
    Zhang, Jingping
    Shi, Xiaobo
    Xing, Fangfang
    Shao, Yang W.
    Wang, Yuanyuan
    Zhang, Xiaozhi
    Wang, Shuwen
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) : 1470 - 1474
  • [46] An experimental model for in vivo treatment with ALK inhibitors of EML4-ALK-positive lung cancer
    Soda, Manabu
    Takada, Shuji
    Takeuchi, Kengo
    Hatanaka, Hisashi
    Yamashita, Yoshihiro
    Ishikawa, Yuichi
    Sugiyama, Yukihiko
    Mano, Hiroyuki
    CANCER RESEARCH, 2009, 69
  • [47] 非小细胞肺癌患者eml4-alk基因检测及eml4-alk阳性患者临床特征分析
    符萌
    冷再君
    李传应
    侯丹阳
    邵璐
    张安莉
    操乐杰
    安徽医科大学学报, 2017, 52 (04) : 528 - 533
  • [48] Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
    Lei, Xi
    Zhu, Shuai
    Ren, Dian
    Ren, Fan
    Li, Tong
    Zhou, Ning
    Li, Shuo
    Shi, Tao
    Zu, Lingling
    Song, Zuoqing
    Chalubinska-Fendler, Justyna
    Denis, Marc G.
    Bernicker, Eric H.
    de Montpreville, Vincent Thomas
    Jiang, Richeng
    Xu, Song
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (06) : 1176 - 1184
  • [49] Identification of EML4-ALK fusion in a sporadic case of cholangiocarcinoma
    Trombetta, Domenico
    Parente, Paola
    Latiano, Tiziana Pia
    Fabrizio, Federico Pio
    Muscarella, Lucia Anna
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 71 : 92 - 94
  • [50] Analysis of EML4-ALK fusion transcripts in plasma and platelets to monitor response to crizotinib in EML4-ALK positive non-small cell lung cancer patients (NSCLC)
    Aguado, Cristina
    Teixido, Cristina
    Gimenez-Capitan, Ana
    Gil, Maria de los Llanos
    Rodriguez, Sonia
    Viteri, Santiago
    Karachaliou, Niki
    Aldeguer, Erika
    Peg, Vicente
    Alonso, Lidia
    Molina-Vila, Miguel Angel
    Rosell, Rafael
    CANCER RESEARCH, 2017, 77
12345